Barclays PLC Acquires 41,394 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Barclays PLC increased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 94.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 85,395 shares of the company's stock after acquiring an additional 41,394 shares during the quarter. Barclays PLC owned approximately 0.13% of Vera Therapeutics worth $3,774,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of VERA. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock valued at $86,000 after purchasing an additional 350 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new position in Vera Therapeutics during the second quarter valued at about $135,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vera Therapeutics during the second quarter worth about $163,000. Quarry LP purchased a new stake in Vera Therapeutics during the second quarter worth about $235,000. Finally, AlphaCentric Advisors LLC bought a new stake in Vera Therapeutics in the third quarter worth about $332,000. 99.21% of the stock is currently owned by institutional investors.

Insider Activity at Vera Therapeutics

In other news, Director Beth C. Seidenberg sold 15,000 shares of the firm's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $48.03, for a total transaction of $720,450.00. Following the sale, the director now owns 131,553 shares in the company, valued at approximately $6,318,490.59. This trade represents a 10.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marshall Fordyce sold 23,125 shares of the company's stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $46.05, for a total transaction of $1,064,906.25. Following the completion of the transaction, the chief executive officer now owns 307,972 shares of the company's stock, valued at $14,182,110.60. This trade represents a 6.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 108,125 shares of company stock valued at $4,740,588. Company insiders own 21.70% of the company's stock.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock traded down $0.08 on Monday, reaching $42.52. The stock had a trading volume of 81,383 shares, compared to its average volume of 872,765. The business's 50 day moving average is $45.27 and its two-hundred day moving average is $40.49. The company has a market cap of $2.69 billion, a P/E ratio of -16.29 and a beta of 1.08. Vera Therapeutics, Inc. has a 1 year low of $14.20 and a 1 year high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $107.00 price target on shares of Vera Therapeutics in a research note on Tuesday, October 1st. JPMorgan Chase & Co. increased their price objective on Vera Therapeutics from $72.00 to $75.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Scotiabank assumed coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $60.00 target price on the stock. Guggenheim increased their price target on Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a research note on Monday, October 28th. Finally, Wells Fargo & Company started coverage on Vera Therapeutics in a research note on Thursday, November 21st. They issued an "overweight" rating and a $70.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Vera Therapeutics presently has an average rating of "Buy" and an average target price of $59.22.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.